Alkem Laboratories Limited will convene an Extraordinary General Meeting (EGM) on August 17, 2026, to consider and approve the scheme of amalgamation with its wholly-owned subsidiary, Adroit Biomed Limited. The meeting is being held pursuant to an order dated June 10, 2026, passed by the Hon’ble National Company Law Tribunal (NCLT), Mumbai Bench. The amalgamation aims to consolidate the operations of the transferor company, Adroit Biomed, into Alkem Laboratories, the transferee company.

The scheme, approved by the respective boards of Alkem Laboratories and Adroit Biomed on February 13, 2026, and February 11, 2026, proposes that all properties, assets, and liabilities of Adroit Biomed will vest in Alkem Laboratories upon the scheme becoming effective. As Adroit Biomed is a wholly owned subsidiary, no new shares or cash consideration will be issued by Alkem Laboratories for the amalgamation. The shares held by Alkem Laboratories in Adroit Biomed will stand cancelled.

Meeting and Voting Details

The EGM will be conducted through video conferencing (VC) or other audio-visual means (OAVM) on Monday, August 17, 2026, at 11:00 a.m. IST. The deemed venue for the meeting is the registered office of Alkem Laboratories at Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai. Mr. Harihar Prakash Chaturvedi, Former NCLT Member, has been appointed as the Chairperson of the meeting, and Mr. Ritul Parmar, Practicing Company Secretary, has been appointed as the Scrutinizer.

Equity shareholders of Alkem Laboratories as on the cut-off date of August 10, 2026, are eligible to vote. The company has provided a remote e-voting facility, which will commence on August 12, 2026, at 9:00 a.m. IST and conclude on August 16, 2026, at 5:00 p.m. IST. Shareholders who have not voted remotely may also vote during the meeting via the e-voting facility available through VC/OAVM. The resolution requires approval by a majority of persons representing three-fourths in value of the equity shareholders.

Key Meeting Dates

Rationale and Approvals

The amalgamation is intended to integrate and consolidate business operations, providing operational rationalization and organizational efficiency. It is expected to eliminate duplication of work, reduce overheads, and allow for more efficient capital allocation. The scheme is conditional upon the approval of the requisite majority of shareholders and the subsequent sanction of the NCLT and other regulatory authorities.

The statutory auditors of both companies have confirmed that the accounting treatment proposed in the scheme is in conformity with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013. The notice of the meeting, along with the explanatory statement and the draft scheme, is available on the company's website and has been sent to shareholders.

Alkem Laboratories witnessed significant block trade activity across both major Indian exchanges, with large-lot transactions recorded on the BSE and NSE. The combined value of the two trades stood at ₹139.25 crore, reflecting sustained institutional interest in the pharmaceutical company's stock.

Block Trade Details

The following table summarises the key parameters of the block trades recorded on BSE and NSE:

The BSE transaction involved approximately 182000 shares changing hands at ₹5627.00 per share, amounting to ₹102.41 crore. On the NSE, a separate block trade of approximately 64,869 shares was executed at ₹5679.00 per share, valued at ₹36.84 crore. Block trades of this magnitude typically involve institutional participants and are executed outside the regular order book to minimise market impact. The transactions in Alkem Laboratories underscore continued large-investor interest in the pharmaceutical company's stock.